Sanjay Shukla bought $18k of ATYR
President and CEO at aTYR PHARMA INC. 15,000 shares at an average of $1.18, traded Dec 11, 2023, filed Dec 12, 2023.
Score components
- +25RoleCEO
- 0Trade size$18k at market
- +3Relative to holdingsHoldings up 16%
- +18Price context5% above the 52-week low; 54% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001209191-23-058377, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 11, 2023 | POpen-market purchase Common Stock | +3,000 | $1.17 | $3,510 | 94,173 | Dec 12, 2023 |
| Dec 12, 2023 | POpen-market purchase Common Stock | +12,000 | $1.18 | $14k | 106,173 | Dec 12, 2023 |
Related signals
Other insiders at aTYR PHARMA INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 33Weak | ATYRbuy aTYR PHARMA INC | Paul Schimmel director | $50k 100,000 shares | +15% | |
| 22Weak | aTYR PHARMA INC | Jill Marie Broadfoot Chief Financial Officer | $1,521 1,558 shares | -4% | |
| 15Weak | aTYR PHARMA INC | Nancy Denyes General Counsel | $1,091 1,118 shares | -3% | |
| 25Weak | aTYR PHARMA INC | Sanjay Shukla President and CEO | $3,655 3,745 shares | -2% | |
| 57Moderate | ATYRbuy aTYR PHARMA INC | Paul Schimmel director | $912k 1,000,000 shares | +242% | |
| 25Weak | ATYRbuy aTYR PHARMA INC | Jane A Gross director | $15k 3,750 shares | +63% | |
| 15Weak | aTYR PHARMA INC | Jill Marie Broadfoot Chief Financial Officer | $4,740 1,254 shares | -4% | |
| 8Weak | aTYR PHARMA INC | Nancy Denyes General Counsel | $3,398 899 shares | -3% | |
| 40Moderate | aTYR PHARMA INC | Nancy Denyes General Counsel | $9,276 5,000 shares | +29% | |
| 47Moderate | aTYR PHARMA INC | Jill Marie Broadfoot Chief Financial Officer | $8,950 5,000 shares | +22% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.